We are live on ! Find out more
BCAB icon

BioAtla
BCAB

Fund managers haven’t disclosed any holdings of BCAB yet.

BCAB Hedge Fund Activity: Q1 2026 in Review

36 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in BioAtla (BCAB) for Q1 2026, worth a combined $2.52M — down 66% from $7.49M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of BCAB and 8 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 9 added.

The largest buyer was Millennium Management, adding an estimated $467K. The largest seller was Marshall Wace, cutting an estimated $144K.

  • 36 institutional investors held BioAtla (BCAB) as of Q1 2026, down from 41 in Q4 2025.
  • Funds reported $2.52M of BioAtla stock for Q1 2026, down 66% quarter-over-quarter.
  • 8 funds opened new BioAtla positions in Q1 2026 and 10 closed out, a net change of -2 holders.
  • The largest BioAtla buyer in Q1 2026 was Millennium Management, an estimated $467K added.
  • The largest BioAtla seller in Q1 2026 was Marshall Wace, an estimated $144K sold.

Based on aggregated 13F filings for Q1 2026.